As biotechs young and old rush to Shanghai, Hong Kong, and Beijing in hopes of tapping flush VC funds, several US companies are learning the process isn’t as straightforward as they first thought.
Here at Endpoints News, we spent the last few months asking around to learn what common obstacles are tied with fundraising in China, and what biotech execs should know before diving in. We polled China-based VCs, executives who have closed rounds from Chinese investors, US-based investors who’ve been in syndicates with Chinese investors, and several other experts in the field. Their collective answers make up this piece — part one of a two-part Endpoints series on fundraising in China.
In part two tomorrow, we’ll address the massive influx of biotech cash streaming from the East to the West and give you background and insight on the individual VC partners in China who are making a transpacific splash. These are people who should be on your radar.
But before booking a flight for your fundraising tour of the continent, here's some advice from insiders:
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,100+ biopharma pros who read Endpoints News by email every day.Free Subscription